Dr Ross Camdige speaks to ecancer online about two of his ASCO 2020 virtual presentations which discussed updates using brigatinib.
He outlines the next steps from the findings of the ALEX and ALTA-1L trials using alectinib and brigatinib respectively, which showed superiority to crizotinib. This involves defining a high risk group to investigate further.
The second presentation looks at a pulmonary complication involved with brigatinib, and based on this, how to decide whether brigatinib is a suitable drug for some patients.
This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.